Physician profile
Ami M Shah
NPI 1144781428
$6,158.54
in general payments reported to CMS, 2019-2025
19 companies · $1,681 in 2025
The $1,681 reported for 2025 was more than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $143 · 2022: $556 · 2023: $1,581 · 2024: $2,197 · 2025: $1,681.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,360 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,360.18 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $1,619.48 | 2022-2025 | |
| Amgen INC. | $1,418.66 | 2021-2025 | Evenity, Enbrel, Tavneos |
| Ucb, INC. | $775.31 | 2022-2025 | Cimzia, Bimzelx |
| Janssen Biotech, INC. | $530.86 | 2024 | Tremfya, Simponi Aria |
| Astrazeneca Pharmaceuticals LP | $324.95 | 2023-2025 | Saphnelo |
| Lilly USA, LLC | $192.79 | 2022-2025 | Taltz |
| Boehringer Ingelheim Pharmaceuticals, INC. | $191.57 | 2022-2024 | Ofev |
| Glaxosmithkline, LLC. | $164.54 | 2023-2024 | Benlysta |
| Abbvie INC. | $154.79 | 2023 | Rinvoq, Skyrizi |
| E.R. Squibb & Sons, L.L.C. | $125.00 | 2021 | |
| Scpharmaceuticals INC. | $121.83 | 2025 | |
| Sobi, INC | $119.43 | 2022-2024 | |
| Janssen Scientific Affairs, LLC | $108.01 | 2024-2025 | Tremfya |
| Organon LLC | $86.77 | 2023 | |
| Pfizer INC. | $69.05 | 2023-2024 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fresenius Kabi USA, LLC | $64.48 | 2023-2024 | Idacio |
| Novartis Pharmaceuticals Corporation | $58.38 | 2025 | |
| Horizon Therapeutics Plc | $18.33 | 2022 | |
| Aurinia Pharma U.S., INC. | $14.31 | 2023 | Lupkynis |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ami Shah listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.